Dokumendiregister | Ravimiamet |
Viit | REP-1/1809-1 |
Registreeritud | 17.05.2024 |
Sünkroonitud | 20.05.2024 |
Liik | Sissetulev kiri |
Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
Toimik | REP-1/2024 |
Juurdepääsupiirang | Avalik |
Juurdepääsupiirang | |
Adressaat | European Directorate for the Quality of Medicines & HealthCare |
Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
Vastutaja | Signe Leito (RA, Labor) |
Originaal | Ava uues aknas |
1
Signe Leito
Saatja: [email protected] Saatmisaeg: reede, 26. aprill 2024 15:39 Adressaat: Signe Leito Teema: For action: Proposed addition to the work programme of Group 17 - Sitagliptin malate: EDQM-2024-01782-mail
Please make sure to include in any reply our mail reference: EDQM-2024-01782-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear Colleagues, Please find below the link to a survey being carried out concerning the proposed addition of Sitagliptin malate to the work programme of Group 17. In order to have access to the survey, please copy and paste the link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=733794&newtest=Y&lang=en Deadline for replies: 29 May 2024 Thank you. With kind regards On behalf of Isabelle Mercier Villy Nikolova Administrative Support Assistant European Pharmacopoeia Department EDQM Council of Europe Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://www.edqm.eu/store Stay connected with the EDQM
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
2
**************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2024-01782-mail
Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
---|